PHASE-I AND PHARMACOKINETIC STUDY OF RECOMBINANT HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR GIVEN IN COMBINATION WITH FLUOROURACIL PLUS CALCIUM LEUCOVORIN IN METASTATIC GASTROINTESTINAL ADENOCARCINOMA

被引:37
作者
GREM, JL
MCATEE, N
MURPHY, RF
HAMILTON, JM
BALIS, F
STEINBERG, S
ARBUCK, SG
SETSER, A
JORDAN, E
CHEN, A
KOHLER, DR
KOTITE, B
ALLEGRA, CJ
机构
[1] NCI,DIV CANC TREATMENT,CANC THERAPY EVALUAT PROGRAM,BETHESDA,MD 20892
[2] NIH,WARREN GRANT MAGNUSON CLIN CTR,CANC NURSING SERV,BETHESDA,MD 20892
[3] NIH,WARREN GRANT MAGNUSON CLIN CTR,DEPT PHARM,BETHESDA,MD 20892
关键词
D O I
10.1200/JCO.1994.12.3.560
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the toxicities and potential for dose escalation of intravenous (IV) bolus fluorouracil (5-FU) given with 500 mg/m2/d leucovorin (LCV) and granulocyte-macrophage colony-stimulating factor (GM-CSF). Patients and Methods: Thirty-seven patients received escalating doses of 5-FU/LCV on days 1 to 5 with subcutaneous GM-CSF either 5 or 10 μg/kg/d starting on day 6 or 3 μg/kg/d starting on day 1. 5-FU was escalated from 370 mg/m2/d by 15% increments between patient cohorts and within patients according to tolerance. Results: With GM-CSF starting on day 6, dose-limiting toxicity occurred during cycle no. 1 in all three patients entered at 5-FU 490 mg/m2/d. However, individual patients tolerated 5-FU doses up to 644 mg/m2/d. When all cycles were analyzed, grade 3 to 4 mucositis and grade 4 granulocytopenia complicated ≤ 15% and ≤ 6% of cycles with 5-FU doses ≤ 560 mg/m2/d (115 cycles). With GM-CSF starting on day 1, dose-limiting granulocytopenia occurred during cycle no. 1 in five of 10 patients entered at 5-FU 490 mg/m2/d. Although the granulocyte nadirs were significantly lower at each 5-FU dose level with the concurrent GM-CSF schedule (eg, 490 mg/m2/d: median, 879/μL v 3,286/μL; two-tailed P[P2] < .001), dose- limiting granulocytopenia complicated ≤ 16% of cycles with 5-FU ≤ 560 mg/m2/d (99 cycles); ≥ grade 3 mucositis occurred in ≤20% of cycles. Grade 3 to 4 diarrhea was unusual with either GM-CSF schedule. Most patients treated with GM-CSF ≥ 5 μg/kg/d required dose reductions for constitutional toxicity; 3.0 to 3.8 μg/kg/d was better tolerated. Venous thrombosis occurred in 17% of patients (concurrent v sequential GM-CSF, 29% v 5%; P2 = .08). The median delivered 5-FU dose-intensity for GM-CSF starting either on day 6 or on day 1 was 615 and 647 mg/m2/wk (P2 = .41), respectively. Pharmacologic exposure to 5-FU increased with higher doses of 5-FU, and concurrent GM-CSF administration did not affect 5-FU clearance. Conclusion: A starting dose of 425 mg/m2/d of 5-FU with LCV on days 1 to 5 could be safely combined with GM-CSF starting either on day 1 or day 6, with further 5-FU dose escalation according to individual tolerance.
引用
收藏
页码:560 / 568
页数:9
相关论文
共 36 条
[1]   EFFECT OF RECOMBINANT HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR ON CHEMOTHERAPY-INDUCED MYELOSUPPRESSION [J].
ANTMAN, KS ;
GRIFFIN, JD ;
ELIAS, A ;
SOCINSKI, MA ;
RYAN, L ;
CANNISTRA, SA ;
OETTE, D ;
WHITLEY, M ;
FREI, E ;
SCHNIPPER, LE .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (10) :593-598
[2]   EFFECT OF RECOMBINANT HUMAN GRANULOCYTE MACROPHAGE COLONY-STIMULATING FACTOR ON HEMATOPOIETIC RECONSTITUTION AFTER HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS BONE-MARROW TRANSPLANTATION [J].
BRANDT, SJ ;
PETERS, WP ;
ATWATER, SK ;
KURTZBERG, J ;
BOROWITZ, MJ ;
JONES, RB ;
SHPALL, EJ ;
BAST, RC ;
GILBERT, CJ ;
OETTE, DH .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (14) :869-876
[3]  
CONTI JA, 1992, CANCER, V70, P2699, DOI 10.1002/1097-0142(19921201)70:11<2699::AID-CNCR2820701122>3.0.CO
[4]  
2-C
[5]   REDUCTION BY GRANULOCYTE COLONY-STIMULATING FACTOR OF FEVER AND NEUTROPENIA INDUCED BY CHEMOTHERAPY IN PATIENTS WITH SMALL-CELL LUNG-CANCER [J].
CRAWFORD, J ;
OZER, H ;
STOLLER, R ;
JOHNSON, D ;
LYMAN, G ;
TABBARA, I ;
KRIS, M ;
GROUS, J ;
PICOZZI, V ;
RAUSCH, G ;
SMITH, R ;
GRADISHAR, W ;
YAHANDA, A ;
VINCENT, M ;
STEWART, M ;
GLASPY, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (03) :164-170
[6]   VASCULAR TOXICITY ASSOCIATED WITH ANTINEOPLASTIC AGENTS [J].
DOLL, DC ;
RINGENBERG, QS ;
YARBRO, JW .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (09) :1405-1417
[7]   A RANDOMIZED TRIAL OF FLUOROURACIL AND FOLINIC ACID IN PATIENTS WITH METASTATIC COLORECTAL-CARCINOMA [J].
ERLICHMAN, C ;
FINE, S ;
WONG, A ;
ELHAKIM, T .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (03) :469-475
[8]   EFFECT OF GRANULOCYTE COLONY-STIMULATING FACTOR ON NEUTROPENIA AND ASSOCIATED MORBIDITY DUE TO CHEMOTHERAPY FOR TRANSITIONAL-CELL CARCINOMA OF THE UROTHELIUM [J].
GABRILOVE, JL ;
JAKUBOWSKI, A ;
SCHER, H ;
STERNBERG, C ;
WONG, G ;
GROUS, J ;
YAGODA, A ;
FAIN, K ;
MOORE, MAS ;
CLARKSON, B ;
OETTGEN, HF ;
ALTON, K ;
WELTE, K ;
SOUZA, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (22) :1414-1422
[9]  
GREM JL, 1991, SEMIN ONCOL, V18, P17
[10]  
GREM JL, 1987, CANCER TREAT REP, V71, P1249